8-K: Marpai Secures $650K in Private Stock Placement

Marpai, Inc. announced a private placement of Class A common stock, raising approximately $650,000, with significant participation from its CEO's controlled entity.

Summary

• Marpai, Inc. entered into a Securities Purchase Agreement on July 29, 2025, for a private placement of its Class A common stock.
• The company agreed to issue and sell an aggregate of 603,640 shares of its Class A common stock.
• The shares were sold at a purchase price of $1.0768 per share, totaling approximately $650,000 in gross proceeds.
• Three investors participated in the private placement, including HillCour Investment Fund, LLC, an entity controlled by Marpai's Chief Executive Officer, Damien Lamendola.
• HillCour Investment Fund, LLC purchased 371,470 shares of Common Stock, representing approximately $400,000 of the total proceeds.
• The securities issued are exempt from registration requirements under Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506(b) of Regulation D.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding and liquidity, which is positive. However, the significant dilution and the large portion taken by a related party (CEO's entity) temper the overall positive sentiment, suggesting a potential challenge in attracting broader external investment or a critical need for funds.

Positives

• The private placement provides Marpai, Inc. with approximately $650,000 in capital, enhancing liquidity and financial flexibility.
• Significant participation from the CEO's controlled entity (HillCour Investment Fund, LLC) in the capital raise may signal management's confidence in the company's future.

Negatives

• The issuance of 603,640 new shares will result in dilution for existing shareholders.
• A substantial portion of the capital raise (approximately $400,000 out of $650,000) came from an entity controlled by the CEO, which could raise questions about the company's ability to attract broader, unaffiliated institutional investment for this round.

Risks

• The securities issued in the private placement have not been registered under the Securities Act and are subject to transfer restrictions, meaning they may not be sold in the United States absent registration or an exemption.
• The company's ability to perform its obligations under the Transaction Documents is subject to no Material Adverse Effect occurring, which is defined broadly to include impacts on legality, validity, enforceability, results of operations, assets, business, prospects, or financial condition.
• The company must comply with disclosure obligations under Rule 506(e) regarding 'Bad Actor' disqualifications, and any such event could impact the offering.

Future Outlook

The filing does not provide specific forward-looking statements or guidance regarding the company's operational or financial performance beyond the completion of this capital raise.

Management Comments

• The Securities Purchase Agreement was signed by Steve Johnson, Chief Financial Officer of Marpai, Inc.
• The Form 8-K was signed by Damien Lamendola, Chief Executive Officer of Marpai, Inc.

Industry Context

This capital raise is a company-specific event aimed at strengthening Marpai's financial position. Without further context on the company's business operations or market conditions, it is difficult to assess its relation to broader industry trends, though capital raises are common for growth-oriented companies in the healthcare technology or insurance sectors.

Comparison to Industry Standards

• NA

Related Party Transactions

• HillCour Investment Fund, LLC, an entity controlled by Marpai's Chief Executive Officer, Damien Lamendola, purchased 371,470 shares of Class A common stock in the private placement.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The capital raise provides the company with additional funds, which could support operations, strategic initiatives, or reduce debt, potentially benefiting the company's long-term stability and prospects.

Next Steps

• The company will timely file a Form D with respect to the Securities as required under Regulation D.
• The company will take necessary actions to obtain an exemption for, or to qualify the Securities for, sale under applicable state securities or Blue Sky laws.

Key Dates

Recommendation

The capital raise provides essential funding and liquidity, which is a positive for the company's operational stability. However, the significant dilution from the new share issuance and the substantial participation by a related party (CEO's entity) warrant a cautious 'hold' recommendation. Investors should monitor how these funds are utilized and await further operational and financial updates to assess the long-term impact and the company's ability to generate sustainable growth.

Keywords

Private Placement, Equity Raise, Common Stock, SEC Filing, Form 8-K, Marpai Inc., MRAI, Unregistered Securities, Capital Infusion, Insider Participation